Phaseline

Targets › RPTOR

RPTOR (Regulatory-associated protein of mTOR): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2027.

Component of the mechanistic target of rapamycin complex 1 (mTORC1), an evolutionarily conserved central nutrient sensor that stimulates anabolic reactions and macromolecule biosynthesis to promote cellular biomass generation and growth. In response to nutrients, growth factors or amino acids, mTORC1 is recruited to the lysosome membrane and promotes protein, lipid and nucleotide synthesis by phosphorylating several…. (UniProt, Q8N122)

Open in Phaseline: the race on RPTOR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Theodore S. JohnsonIndoximod
mTORC1 activator
MTOR, RPTOR, MLST8Phase 2Glioblastoma; EpendymomaDec 2027

Conditions

Glioblastoma (1) Ependymoma (1)

Modalities

small molecule (1)

Companies

Theodore S. Johnson (1)

Related targets

MTOR (1) MLST8 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.